Circulating tumor cells: Utility for predicting response to anti-EGFR therapies?

Expert Review of Molecular Diagnostics

Volumn 9, Issue 2, 2009, Pages 115-119

  Mata, Marielena ^a   Raponi, Mitch ^a  

^a CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; PANITUMUMAB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR;

BREAST CANCER; CELL ISOLATION; COLORECTAL CANCER; EDITORIAL; GENE MUTATION; HUMAN; POLYMERASE CHAIN REACTION; PROSTATE CANCER; TREATMENT RESPONSE; TUMOR CELL; ART; DRUG ANTAGONISM; MONITORING; NEOPLASM; SENSITIVITY AND SPECIFICITY; TUMOR EMBOLISM;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; MONITORING, PHYSIOLOGIC; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; PORTRAITS AS TOPIC; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY;

EID: 66549100542     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.9.2.115     Document Type: Editorial

References (21)

1. Raponi M, Winkler H, Dracopoli NC. KRAS mutations predict response to EGFR inhibitors. Curr. Opin. Pharmacol. 8(4), 413-418 (2008).
2. Datta YH, Adams PT, Drobyski WR et al. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J. Clin. Oncol. 12(3), 475-482 (1994).
3. Schoenfeld A, Kruger KH, Gomm J et al. The detection of micrometastases in the peripheral blood and bone marrow of patients with breast cancer using immunohistochemistry and reverse transcriptase polymerase chain reaction for keratin 19. Eur. J. Cancer 33(6), 854-861 (1997).
4. Nagrath S, Sequist LV, Maheswaran S et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450(7173), 1235-1239 (2007).
5. Ignatiadis M, Xenidis N, Perraki M et al. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J. Clin. Oncol. 25(33), 5194-5202 (2007).
6. Stathopoulou A, Vlachonikolis I, Mavroudis D et al. Molecular detection of cytokeratin- 19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J. Clin. Oncol. 20(16), 3404-3412 (2002).
7. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351(8), 781-791 (2004).
8. Danila DC, Heller G, Gignac GA et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin. Cancer Res. 13(23), 7053-7058 (2007).
9. Shaffer DR, Leversha MA, Danila DC et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin. Cancer Res. 13(7), 2023-2029 (2007).
10. Cohen SJ, Punt CJ, Iannotti N et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(19), 3213-3221 (2008).
11. Deng G, Herrler M, Burgess D et al. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients. Breast Cancer Res. 10(4), R69 (2008).
12. Ntouroupi TG, Ashraf SQ, McGregor SB et al. Detection of circulating tumour cells in peripheral blood with an automated scanning fluorescence microscope. Br. J. Cancer 99(5), 789-795 (2008).
13. Zieglschmid V, Hollmann C, Gutierrez B et al. Combination of immunomagnetic enrichment with multiplex RT-PCR analysis for the detection of disseminated tumor cells. Anticancer Res. 25(3A), 1803-1810 (2005).
14. Lankiewicz S, Rivero BG, Bocher O. Quantitative real-time RT-PCR of disseminated tumor cells in combination with immunomagnetic cell enrichment. Mol. Biotechnol. 34(1), 15-27 (2006).
15. Maheswaran S, Sequist LV, Nagrath S et al. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359(4), 366-377 (2008).
16. Hayes DF, Smerage J. Is there a role for circulating tumor cells in the management of breast cancer? Clin. Cancer Res. 14(12), 3646-3650 (2008).
17. Fehm T, Becker S, Duerr-Stoerzer S et al. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res. 9(5), R74 (2007).
18. Meng S, Tripathy D, Shete S et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc. Natl Acad. Sci. USA 101(25), 9393-9398 (2004).
19. Lankiewicz S, Rother E, Zimmermann S et al. Tumour-associated transcripts and EGFR deletion variants in colorectal cancer in primary tumour, metastases and circulating tumour cells. Cell. Oncol. 30(6), 463-471 (2008).
20. Payne RE, Yague E, Slade MJ et al. Measurements of EGFR expression on circulating tumor cells are reproducible over time in metastatic breast cancer patients. Pharmacogenomics 10 (1), 51-57 (2009).
21. Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res. 14(10), 2895-2899 (2008).